Expanded eligibility criteria for COVID-19 oral antiviral treatments, Paxlovid^® (nirmatrelvir and ritonavir) and molnupiravir (Lagevrio^®)

10 July 2022

Commencing 11 July 2022, the eligibility criteria for COVID-19 oral antiviral treatments, nirmatrelvir and ritonavir (Paxlovid^®) and molnupiravir (Lagevrio^®), will be expanded.

New eligibility includes updated age limits and risk factors.

Additional information can be found in the following:

• Addendum - COVID-19 oral antiviral treatments (PDF 226KB)
• Fact sheet - Paxlovid^® (nirmatrelvir and ritonavir) PBS listing (July 2022) (PDF 244KB) - (Word 34KB)
• Fact sheet - Lagevrio^® (molnupiravir) PBS listing (July 2022) (PDF 31KB) - (Word 171KB)
• Fact sheet - Changes to PBS eligibility for COVID-19 treatments - Information for prescribers and pharmacists (PDF 27KB) - (Word 128KB)